OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
October 19, 2015.
Daiichi Sankyo will "reorganize its U.S. Commercial organization as it transfers to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology", the company has announced.
The company says it "will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations". It expects to eliminate 1,000 to 1,200 positions across the country, from the Commercial Home Office, located in Parsippany, NJ, and field-based sales and other positions throughout the country. The company added that the reorganization is not focused on the U.S.-based R&D function concentrated in Edison, NJ, or the packaging plant in Bethlehem, PA.